Stocktoria
VERTEX PHARMACEUTICALS INC / MA VRTX
VERTEX PHARMACEUTICALS INC / MA (VRTX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $12.0B at a 32.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-05 | Truist Securities | Buy (main) |
| 2026-08-05 | Barclays | Overweight (main) |
| 2026-08-04 | TD Cowen | Buy (main) |
| 2026-08-04 | Cantor Fitzgerald | Overweight (main) |
| 2026-08-04 | Canaccord Genuity | Hold (main) |
| 2026-07-13 | UBS | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.286 |
| Retained earnings / assets | 0.529 |
| EBIT / assets | 0.163 |
| Equity / liabilities | 2.675 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 7/9 | -0.41 | 84.8 | +4.3% |
| OGN | Organon & Co. | 5/9 | — | 19 | -2.9% |
About VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
FAQ
Is VRTX financially healthy?
VERTEX PHARMACEUTICALS INC / MA's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VRTX pay a dividend?
No, VERTEX PHARMACEUTICALS INC / MA does not currently pay a dividend.
How profitable is VRTX?
In FY2025, VERTEX PHARMACEUTICALS INC / MA had a net margin of 32.9% and a return on equity of 21.2%.
Is VRTX overvalued or undervalued?
VERTEX PHARMACEUTICALS INC / MA trades at about 34.3× trailing earnings — above its 10-year norm (10-year range 22.3×–263.9×, median 30.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for VRTX?
The average Wall-Street price target for VERTEX PHARMACEUTICALS INC / MA is $570.32, about 8.4% above the recent price, from 28 analysts (consensus: buy).
Is VRTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VERTEX PHARMACEUTICALS INC / MA: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 29.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.